



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail  
Emily Hill  
Chief Financial Officer  
PTC Therapeutics, Inc.  
100 Corporate Court  
South Plainfield, NJ 07080

**Re: PTC Therapeutics, Inc.**  
**From 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit 10.5 - Lease Agreement dated as of August 3, 2019, by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc.**  
**Filed October 30, 2019**  
**File No. 001-35969**

**Form 8-K**  
**Exhibit No. 2.1 - Asset Purchase Agreement by and between PTC Therapeutics, Inc. and BioElectron, dated October 1, 2019**  
**Filed October 30, 2019**  
**File No. 001-35969**

Dear Ms. Hill:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance